View Older Stories View More Recent Stories
-
Biogen (BIIB) PT Raised to $130 at UBS
-
JPMorgan Reiterates Neutral Rating on Biogen (BIIB)
-
RBC Capital on Biogen (BIIB): 'Long-Term Vision Coming Together'
-
Biogen (BIIB) sees $0.26 per share charge in Q2
-
Biogen (BIIB) Updates Q2 Guidance
-
These 30 global stocks offer tactical and structural upside, says RBC
-
RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimer’s market
-
Biogen (BIIB) Initiates Phase 3 Study of Felzartamab
-
RBC: "How LLY Could Blaze a Trail and BIIB Could Pull AHEAD In The Large, Overlooked Pre-Sx AD Mkt"
-
H.C. Wainwright on Biogen (BIIB): 'Salanersen can help cement Biogen’s leadership in SMA'
-
Biogen (BIIB) to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
-
Biogen (BIIB) Initiates Phase 3 Pediatric Study of Omaveloxolone
-
UBS Reiterates Neutral Rating on Biogen (BIIB)
-
Jefferies: 'We highlight multiple de-risked or commercial-stage names that we think have promising M&A potential'
-
H.C. Wainwright Reiterates Buy Rating on Biogen (BIIB)
-
Stifel weighs in on Biogen (BIIB) following R&D event
-
Entrada Therapeutics (TRDA) Appoints Maha Radhakrishnan to its Board
-
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB)
-
Biogen (BIIB) PT Lowered to $187 at H.C. Wainwright
-
Biogen (BIIB) PT Lowered to $220 at Canaccord Genuity
-
Stifel Reiterates Hold Rating on Biogen (BIIB) Following EPS
-
Biogen (BIIB) Tops Q1 EPS by 6c; cuts guidance
-
Biogen (BIIB) PT Lowered to $199 at Truist Securities
-
HSBC cuts biotech stocks: Eli Lilly lowered to Reduce
-
HSBC Downgrades Biogen (BIIB) to Hold
-
BTIG Reiterates Neutral Rating on Biogen (BIIB)
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
Biogen (BIIB) PT Lowered to $134 at UBS
-
Pharma stocks slide after Trump signals tariffs on sector
-
Biogen (BIIB) PT Lowered to $221 at RBC Capital
-
Biogen's (BIIB) Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
-
Organon (OGN) Acquires TOFIDENCE
-
Biogen (BIIB) Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
-
These 11 stocks are Mizuho's Aging Intelligence (AI) top picks
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
Biogen (BIIB) and Eisai: CHMP Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
-
Oppenheimer Reiterates Outperform Rating on Biogen (BIIB)
-
Biogen (BIIB) and Stoke Therapeutics (STOK) Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome
-
Piper Sandler on Biogen (BIIB): 'Can Still Get Worse For The Shares'; PT Lowered to $135
-
Biogen (BIIB) PT Lowered to $159 at Bernstein, Reflecting Lowered 2025 Revenue Estimate
-
Biogen (BIIB) PT Lowered to $200 at TD Cowen as '2025 Guidance Reflects Declining MS Franchise'
-
Biogen (BIIB) PT Lowered to $225 at RBC Capital
-
Biogen (BIIB) PT Lowered to $210 at Truist Securities; 'Focus on Topline Growth/Pipeline'
-
Biogen (BIIB) PT Lowered to $241 at H.C. Wainwright
-
Biogen (BIIB) PT Lowered to $139 at BMO Capital; 'No Easy Answers to Get Back to Growth'
-
Biogen (BIIB) PT Lowered to $224 at Scotiabank
-
Biogen (BIIB) Tops Q4 EPS by 3c; offers outlook
-
Royalty Pharma plc (RPRX) Announces R&D Funding Collaboration With Biogen
-
Biogen (BIIB) Biogen Q4 earnings preview: here’s what to expect
-
Biogen (BIIB) February 14 weekly option implied volatility into quarter results
